TSHATaysha Gene Therapies, Inc.
$3.97-22% 1Y
$3.97
$3.5052 weeks$6.98
Is the price fair?
What TSHA's price assumes
Taysha Gene Therapies, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 236× revenue.
236
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 3.34
Price / book · today's price, trailing year to Jun 30, 2026
- EV / sales
- 161
EV / sales
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 3.34
- EV / EBIToperating margin −2792%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 30, 2026
- 161
- Market capitalisation325.8 million shares, counted Aug 11, 2026
- $1.29B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
On our screens:Most shorted stocks